uniQure (NASDAQ:QURE) Shares Gap Up – What’s Next?

uniQure N.V. (NASDAQ:QURE)’s stock price gapped up before the market opened on Monday. The stock had previously closed at $24.83, but opened at $26.22. uniQure shares last traded at $23.3850, with a volume of 1,996,815 shares.

Wall Street Analysts Forecast Growth

QURE has been the topic of several research reports. HC Wainwright reiterated a “buy” rating on shares of uniQure in a report on Tuesday, September 29th. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Wednesday, July 29th. UBS Group started coverage on shares of uniQure in a report on Thursday, October 15th. They set a “buy” rating and a $48.00 price objective for the company. Finally, William Blair upgraded uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.25.

uniQure Stock Down 3.6%

The company has a fifty day moving average of $34.55 and a 200 day moving average of $29.67. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.66 billion, a P/E ratio of -5.98 and a beta of 1.14.

Institutional Trading of uniQure

Several large investors have recently added to or reduced their stakes in QURE. Mirae Asset Global Investments Co. Ltd. bought a new stake in uniQure during the 3rd quarter valued at approximately $86,000. China Universal Asset Management Co. Ltd. bought a new position in shares of uniQure during the third quarter valued at approximately $310,000. Maxi Investments CY Ltd purchased a new stake in shares of uniQure during the third quarter valued at about $966,000. IFP Advisors Inc boosted its holdings in uniQure by 18.0% in the third quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 500 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in uniQure during the 3rd quarter worth about $121,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.